Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis
Status:
Completed
Trial end date:
2018-05-31
Target enrollment:
Participant gender:
Summary
The DOLF Triple Drug Therapy for Lymphatic Filariasis study will determine the frequency,
type and severity of adverse events following triple-drug therapy (IVM+DEC+ALB, IDA) compared
to the standard two-drug treatment (DEC+ALB, DA) in infected and uninfected individuals in a
community in 5 different countries. The objective is to acquire safety, efficacy, and
acceptability data to assess the safety and acceptability of the IDA drug combination.
Phase:
N/A
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
Case Western Reserve University Indian Council of Medical Research